위암 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global stomach cancer treatment market size is expected to reach USD 19.91 Billion in 2034 from USD 6.56 Billion in 2025, growing at a CAGR of 13.13% during 2026-2034.This market is expanding as advances in oncology improve the range of treatment options available for patients diagnosed with stomach cancer. Treatment approaches may include surgery, chemotherapy, radiation therapy in selected cases, targeted therapies, and immunotherapy, depending on the disease stage and tumor characteristics. Increasing awareness of gastric cancer, improvements in diagnostic procedures, and broader access to specialist oncology services are supporting treatment demand. Healthcare providers are also placing greater emphasis on identifying molecular characteristics that can help guide therapy selection. These developments are encouraging pharmaceutical research and investment in more individualized stomach cancer treatment strategies.

Market growth is driven by innovations in cancer medicines, increasing clinical research activity, and the expanding use of biomarker testing. Pharmaceutical companies are developing therapies that target specific proteins, genetic alterations, and immune pathways associated with stomach cancer. Improved surgical techniques and multidisciplinary treatment planning are also helping healthcare teams coordinate care more effectively. Diagnostic laboratories are expanding their capabilities to identify biomarkers that may influence treatment decisions. Furthermore, collaborations between research institutions, biotechnology companies, and healthcare providers are supporting clinical trials and the evaluation of new therapeutic combinations.

The future prospects of this market will depend on the development of more effective treatments, earlier disease detection, and broader access to precision oncology. Research into immunotherapy combinations, targeted medicines, and molecularly guided treatment selection may provide additional options for eligible patients. Advances in liquid biopsy and tumor profiling could also support treatment monitoring and the identification of resistance mechanisms. However, treatment costs, adverse effects, late diagnosis, and differences in access to advanced oncology services remain significant challenges. Continued clinical research, improved supportive care, and greater availability of diagnostic testing will be important for future market development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy And Surgery (Qualitative Analysis Only)

By Disease Indication

• Gastric Cancer/Gastroesophageal Junction Cancer
• Gastrointestinal Stromal Tumors

By Route Of Administration

• Oral
• Injectable

By Drug Class

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR2 Antagonists
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty & Retail Pharmacies
• Others

COMPANIES PROFILED

• Merck & Co., Bristol Myers Squibb, AstraZeneca, Astellas Pharma, Roche, Eli Lilly, BeiGene, Daiichi Sankyo, Zymeworks, Amgen, Novartis, Pfizer, Sanofi, Takeda, Servier, Jiangsu Hengrui Medicine, Jiangsu Chia Tai Tianqing, Innovent Biologics, Eisai, Regeneron Pharmaceuticals

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL STOMACH CANCER TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Radiation Therapy And Surgery (Qualitative Analysis Only) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Gastric Cancer/Gastroesophageal Junction Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gastrointestinal Stromal Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL STOMACH CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Drug Class
• 7.2. PD-1/PD-L1 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. HER2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. VEGFR2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Specialty & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL STOMACH CANCER TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Disease Indication
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Drug Class
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Disease Indication
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Drug Class
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Disease Indication
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Drug Class
  • 9.4.5 By Distribution Channel
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Disease Indication
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Drug Class
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Disease Indication
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Drug Class
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL STOMACH CANCER TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co
  • 11.2.2 Bristol Myers Squibb
  • 11.2.3 AstraZeneca
  • 11.2.4 Astellas Pharma
  • 11.2.5 Roche
  • 11.2.6 Eli Lilly
  • 11.2.7 BeiGene
  • 11.2.8 Daiichi Sankyo
  • 11.2.9 Zymeworks
  • 11.2.10 Amgen
  • 11.2.11 Novartis
  • 11.2.12 Pfizer
  • 11.2.13 Sanofi
  • 11.2.14 Takeda
  • 11.2.15 Servier
  • 11.2.16 Jiangsu Hengrui Medicine
  • 11.2.17 Jiangsu Chia Tai Tianqing
  • 11.2.18 Innovent Biologics
  • 11.2.19 Eisai
  • 11.2.20 Regeneron Pharmaceuticals